Canadian postmenopausal women with advanced HR+ HER2- breast cancer that have been previously exposed to non-steroidal aromatase inhibitor (NSAI) therapy in either the adjuvant or metastatic setting and currently receiving endocrine therapy (ET) or ET plus targeted therapy (TT).